Skip to content
Lower risk Drug recall · FDA · Published March 16, 2023

Northwind Tadalafil 20mg Tablets Recall: CGMP Deviations

Northwind Pharmaceuticals recalls 20mg Tadalafil tablets due to manufacturing quality issues. Affected lots expire by November 2023. Consumers should check product labels for specific lot numbers and expiration dates.

🇺🇸 FDA recall #D-0553-2023DrugNorthwind Pharmaceuticals ›
Take action

Contact the company

Recalling firmNorthwind Pharmaceuticals LLC4838 Fletcher Ave Ste 1000 · Indianapolis, IN 46203-1642
✎ GovInfoNow plain-language explainer

What happened, in plain English

Northwind Pharmaceuticals is recalling 20mg Tadalafil tablets that were repackaged by their company. The recall is due to CGMP (Current Good Manufacturing Practice) deviations, which means the product may not meet safety standards. This recall affects people who have these specific bottle sizes and lot numbers. Read more at govinfonow.com/recall/33797-northwind-tadalafil-20mg-tablets-recall-cgmp-deviations.

Source Summary by GovInfoNow · govinfonow.com/recall/33797-northwind-tadalafil-20mg-tablets-recall-cgmp-deviations · Updated August 17, 2026 · FDA enforcement record: FDA #D-0553-2023

Cite this page

“Northwind Tadalafil 20mg Tablets Recall: CGMP Deviations.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/33797-northwind-tadalafil-20mg-tablets-recall-cgmp-deviations. Based on FDA recall #D-0553-2023 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0553-2023%22&limit=1).

Why it’s dangerous

CGMP deviations refer to failures in the manufacturing process that could affect the product's safety and quality. These deviations mean the tablets might not meet the required standards for safe use, but the specific risk is not described as causing serious injury in normal use.

Who’s affected

People who have the 6-count or 15-count bottles of Tadalafil Tablets, USP 20mg with the listed lot numbers and expiration dates are affected. Those who use prescription medications for erectile dysfunction are most at risk.

How to tell if you have this one

Check the product label for the lot number and expiration date. The affected products are 6-count or 15-count bottles with lot numbers F113892001-F113892203 and expiration dates up to November 2023.

  • Brand
    Northwind Pharmaceuticals
  • Category
    Drug
FDA recall event · 7 products

All 7 products in this recall

FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.

  • Classification
    Class II
  • Status
    Ongoing
  • Distribution
    Nationwide with the United States
Recall numberProduct, codes & lotsQuantityNDC
D-0548-2023Atorvastatin Calcium Tablets, USP, 10 mg, 30-count bottles, Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46203. NDC 51655-946-52; Lot # F117192201, Exp. Date 4/30/202399 bottles51655-946-52
D-0549-2023BusPIRone Hydrochloride Tablets USP, 7.5 mg, 30-count bottles, Rx Only, Repackaged By: NOrthwind Pharmaceuticals, Indianapolis, IN 46203. NDC 51655-511-52; Lot#: F117312201, Exp. Date 06/30/20246 bottles51655-511-52
D-0550-2023Doxazosin Tablets, USP, 4mg, 30-count bottles, Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46203. NDC 51655-109-52; Lot#: F107752201, Exp. Date 05/31/202433 bottles51655-109-52
D-0551-2023Glimepiride Tablets, USP 2mg, packaged in a) 30-count bottles (NDC 51655-383-52), and b)90-count bottles (NDC 51655-383-26), Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46203.; a) Lot #: F106252201, Exp. Date 09/30/2024; F106252301, F106252303, Exp. Date 5/31/2025; F106252304, Exp. Date 07/31/2025 b) Lot #: F106252302, Exp. Date 07/31/2025a) 230 bottles; b) 22 bottles51655-383-26, 51655-383-52
D-0552-2023Glimepiride Tablets, USP 4mg, packaged in a) 30-count bottles (NDC 51655-120-52), and b) 90-count bottles (NDC 51655-120-26), Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46203.; a) Lot #: F105692201, Exp. Date 09/30/2024; F105692203, Exp. Date 02/28/2025 b) Lot #: F105692202, Exp. Date 02/28/2025a) 198 bottles; b) 22 bottles51655-120-52, 51655-120-26
D-0553-2023Tadalafil Tablets, USP 20 mg, packaged in a) 6-count bottles (NDC 51655-473-87), and b) 15-count bottles (NDC 51655-473-54), Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46203.; a) Lot #: F113892002, Exp. Date 08/31/2023; F113892201, Exp. Date 11/30/2023 b) Lot #: F113892001, Exp. Date 08/31/2023; F113892202, Exp. Date 11/30/2023; F113892203, Exp. Date 12/31/2023a)164 bottles; b) 198 bottles51655-473-54, 51655-473-87
D-0554-2023Tadalafil Tablets, USP 5 mg, 30-count bottles, Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46203. NDC 51655-487-52; Lot #: F114302001, Exp. Date 05/31/202323 bottles51655-487-52
Based on the official FDA remedy

What to do — step by step

  1. Check Product Label

    Look for the lot number and expiration date on the bottle to determine if it is affected.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide with the United States” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA published this recall 48 days after the firm started it.

1. Firm started the recall: Mar 16, 202312. FDA classified it Class II: Apr 26, 202323. Published in FDA’s Enforcement Report: May 3, 202332023
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0553-2023 (March 16, 2023) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0553-2023 to see it in context.
  • Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA